Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19
-
- Meng Xianmin
- Department of Pharmacy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
-
- Ling Yun
- Department of Infection, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
-
- Zhang Li
- Department of Pharmacy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
-
- Zhang Qian
- Department of Pharmacy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
-
- Dong Ping
- Department of Pharmacy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
-
- Zhu Tongyu
- Department of Urology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
-
- Lu Hongzhou
- Department of Infection and Imuunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
この論文をさがす
抄録
<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become a serious public health threat to the whole world, and the number of infected is still rising dramatically at this moment. Several studies have confirmed that cytokine storms play a critical role in causing a case to worsen from mild to severe or critical. The current treatment for cytokine storms is limited, so the international medical community is focusing on a specific and effective remedy. Jaktinib hydrochloride is a broad spectrum JAK inhibitor. It can inhibit cytokine-induced immune activation by multiple mechanisms and also slow viral proliferation by inhibiting AAK1 without causing unacceptable toxicity. Jaktinib hydrochloride has great potential for the treatment of patients with coronavirus disease 2019 (COVID-19).</p>
収録刊行物
-
- BioScience Trends
-
BioScience Trends 14 (3), 161-167, 2020-06-30
特定非営利活動法人 バイオ＆ソーシャル・サイエンス推進国際研究交流会
